Aster DM Quality Care Ltd Q3 FY2026 Concall Summary

Key Takeaways

• Merger on track, combined story taking shape: The merger with QCIL is expected to close in Q1 FY27, and management is already providing combined proforma numbers that show a platform with 15% revenue growth, 21% EBITDA margins, and 21% ROCE.
• Kerala cluster is the standout engine: The cluster delivered 20% revenue growth and 190 bps of margin expansion (ex-Kasargod) to 25.4%, powered by a 64% surge in medical value travel and sustained oncology momentum.
• QCIL margin expansion is real and accelerating: Post-Ind AS EBITDA margin expanded 265 bps YoY to 23.7%, with focus units alone delivering 520 bps of expansion, driven by procurement centralization, payor mix improvement, and new clinician hiring.
• The margin dip at Aster is an investment, not a leak: A ~200 bps QoQ margin decline reflects seasonality, the Kasargod startup drag, and deliberate clinical talent investment; management frames it as a ramp-up cost that converts to volume and margin over 3-4 quarters.
• What to watch next quarter: The NCLT-convened shareholder meeting on the merger (expected late Feb to mid-Mar 2026), Kasargod's progress toward breakeven, and whether the K&M cluster's clinician hiring translates into a volume recovery.

The Merger: Timeline, Combined View & Synergies

• Process is in the final stretch: CCI approval and no-objection letters from NSE and BSE are in hand; the merger application was filed with NCLT on December 11, 2025, and the shareholder meeting is expected between February 27 and March 13, 2026, with completion targeted for Q1 FY27.
• Combined proforma is the new lens: Management is voluntarily providing a combined view of Aster and QCIL to help investors assess the platform's underlying economics ahead of legal close, citing complementary footprints, similar clinical philosophies, and consistent operating disciplines.
• The combined platform at a glance: Revenue grew 15% YoY to INR 2,366 crore on 9% patient volume growth and 8% inpatient ARPP improvement; operating EBITDA grew 22% YoY to INR 503 crore at a 21% margin; CONGO mix increased ~150 bps to 54.4%. This performance has been consistent across all three quarters of FY26.
• Synergy math is anchored in procurement: Management identified combining the two entities' INR 1,000 crore each of purchasing power as the first and most sensitive synergy target, with a stated ambition of delivering 10-15% of EBITDA from synergies over the next 2-3 years.
• Combined margin ambition: Management intends to reach a 24-25% margin threshold for the combined entity in 2-3 years, though it declined to quantify the synergy contribution or guide quarter by quarter.

Alisha Moopen: "While the merger process is yet to be consummated, combined performance of the platform reflects how the two organisations are already operating at scale with complementary footprints, similar clinical philosophies, and consistent operating disciplines and provides a clearer view of the earnings capacity and capital efficiency of the platform for the coming years."

QCIL: The Margin Expansion Story

• Headline performance: QCIL revenue rose 17.3% YoY to INR 1,181 crore; post-Ind AS EBITDA grew 32.0% YoY to INR 279 crore, with margins expanding 265 bps YoY to 23.7%.
• What drove the margin: A 100 bps improvement in cash and insurance payor mix to 80.1%, a 60 bps increase in CONGO-T share to 57.6%, a 3.4% YoY reduction in ALOS to 3.9 days, and early gains from procurement centralization and new clinical talent hiring executed in H1 FY26.
• Focus units are the swing factor: These units (~29% of revenue) delivered 19.1% revenue growth and 68.1% EBITDA growth, achieving a 17.8% margin, a ~520 bps YoY expansion driven by sustained operating discipline. Emerging units (~7% of revenue) swung from a loss of INR 1 crore to a profit of INR 10 crore.
• Clinician hiring is paying off: Over 100 clinicians onboarded YTD FY26, with monthly recurring revenue from new cohorts reaching INR 24 crore; these hires are instrumental in shifting the case mix toward higher-acuity care.
• Technology bets are scaling: A partnership with Elekta will deploy five linear accelerators and a first-of-its-kind central planning system; a partnership with Intuitive Surgical will add five robotic systems, making QCIL the first organization to implement robotic surgery at scale across Tier 2 markets.
• Expansion is brownfield-heavy and margin-aware: Of the 1,700+ beds planned over the next 3-4 years (INR 2,000 crore investment), ~1,300 will be in non-metro, Tier-2/3 markets, and ~89-90% of QCIL's expansion is brownfield. Near-term additions in Bhubaneswar and Raipur are not expected to be margin-dilutive because they are either at maxed capacity or adding high-acuity oncology capability.

Varun Khanna: "With the planned acquisition of five robotic systems, we are the first organization to implement robotic surgery at scale across Tier 2 markets. This initiative is our effort to democratize access to cutting-edge surgical care, ensuring patients benefit from the latest advancements in gastroenterology, general surgery & gynecology."

Aster Standalone: Kerala Shines, K&M Stumbles

• Overall Aster performance: Revenue grew 13% YoY to INR 1,186 crore, with 10% patient volume growth and 9% inpatient ARPP improvement. Operating EBITDA grew 11% YoY to INR 224 crore at an 18.9% margin. Excluding the newly commissioned Kasargod hospital, revenue and EBITDA grew 12% and 17% respectively, with margins expanding 90 bps to 20.2%.
• Kerala cluster delivered across the board: Revenue grew 20% YoY to INR 629 crore (19% ex-Kasargod), with inpatient volumes up 11% and ARPP IP up 7%. Operating EBITDA ex-Kasargod grew 28% YoY to INR 157 crore, with margins expanding 190 bps to 25.4%. The expansion came from operating leverage, continued ALOS reduction, and disciplined cost management, even as oncology-led growth pushed material intensity higher.
• Medical value travel is back with force: MVT revenue grew 41% YoY overall, and 64% in Kerala, driven by higher international patient footfall from Maldives, Oman, and other Middle Eastern markets. Management called the recovery sustainable after a temporary setback was resolved through proper engagement.
• K&M cluster softened on clinician churn: Revenue grew only 7% YoY to INR 383 crore, with a 9% decline in inpatient volumes offsetting a strong 17% increase in ARPP IP. The volume softness was attributed to discontinuation of a state scheme at Aster Aadhar and clinician movements driven by heightened competitive intensity in select Bengaluru micro-markets. Occupancy dipped to 55% from 60%.
• The fix is aggressive clinician hiring: Management is targeting the top 1-3 clinicians in each CONGO-T specialty for the Karnataka market and says some who left are already rejoining; it promised that "very big names" will be associated with Aster shortly. Proactive hiring and retention initiatives are expected to improve performance in coming quarters.
• A&T cluster is a quiet improver: Revenue grew 13% YoY to INR 137 crore on 4% IP volume growth and 10% ARPP IP improvement; margins have sequentially improved from 7.9% in Q1 FY26 to 13.2% in Q3 FY26.

Ramesh Kumar: "MVT has grown by 64%. So, that clearly shows that we are back on MVT. And especially from Maldives and Oman is what our patients are flowing in. I think this is definitely sustainable because there was a temporary setback for these patients not coming back."

The Margin Dip: What Happened and Why It Is Not Structural

• The Q3 margin walk: Aster's operating EBITDA margin dipped ~200 bps QoQ. Management attributed this to five factors: (1) Q3 seasonality, which is generally weaker for healthcare; (2) the Kasargod hospital startup drag; (3) investment in clinical talent, particularly adding clinicians in Kerala; (4) a 12% dip in internal medicine, pulmonology, and children's cases due to a 70% reduction in vector-borne diseases; and (5) high growth in oncology (27%) and cardiology (22%), which carry elevated material costs.
• Material cost is the structural watchpoint: Material cost (adjusted for wholesale pharmacy) increased 50 bps YoY, driven by case mix: 60% of the increase from oncology, 20% from neuro (DBS cases doubled), and 20% from robotic procedures. Medical oncology, which is 60% of oncology revenue, carries immunotherapy and targeted therapy with ~70% material cost and average patient yields of INR 4-7 lakhs. Management expects to get material cost back below 21%.
• Management frames this as an investment: The clinician additions are expected to ramp up over 3-4 quarters, converting into volume and margin benefits. The core hospitals and clinics business (ex-Kasargod) still delivered 17% EBITDA growth with 90 bps of margin expansion, supporting the argument that the underlying engine is intact.
• Kasargod is tracking to plan: In its third month, the hospital reached 50-55 occupied beds with over 400 OP patients per day, and monthly losses have reduced to INR 2-2.5 crore. Management expects breakeven within the next quarter.

Sunil Kumar: "It's important to note that this is an investment. We need to think of it as an investment so that once the new doctors come on board, start ramping up over 3-4 quarters, you will see the benefits in the volume, benefits in the margin, right?"

Capacity Expansion: The Bed Pipeline

• Aster's pipeline: Over 2,300 beds are planned, taking total capacity to over 7,800 beds through a balanced mix of brownfield and greenfield projects. The pipeline is phased and aligned with demand visibility.
• QCIL's pipeline: Over 1,700 beds in the next 3-4 years, with ~1,300 in non-metro, Tier-2/3 markets. FY27 additions include Bhubaneswar, Raipur, and Kottayam (155-190 beds, all brownfield or census beds in existing facilities). FY28 will see ~780 beds, all brownfield. FY29 and beyond adds another ~750 beds.
• Greenfield timeline shifts: The Sarjapur Road hospital (Bengaluru) has moved from a Feb-end FY27 target to beginning of FY28 due to drawing approval delays; construction has just started. The Hyderabad Women and Child hospital was delayed to add a bunker and will commission in the second half of next year.
• New-unit margin drag is modest and temporary: Management declined to give specific EBITDA loss guidance for each greenfield but offered a broad monthly burn range of INR 2.5-4 crore for the first six months as a modeling input. The Trivandrum greenfield is expected to ramp to 400 OP patients per day and 50-60 occupied beds within three months, benefiting from network leverage with QCIL's existing KIMS asset.
• Kasargod could ramp fast: If the current trajectory holds, management expects the hospital to ramp to its full 180 beds "very quickly." The general pattern is to start at 75-80 beds and add 30-bed increments at 60-65% occupancy; a Tier-2 city typically takes 5-6 years to reach full capacity, while a strong micro-market like Bengaluru may take 2-3 years longer.

Specialty Mix, ALOS & the Oncology Bet

• CONGO-T is the margin lever: Both entities are pushing toward a 60%+ CONGO-T mix. QCIL's mix reached 57.6% (up 60 bps YoY) and is expected to reach the mid-60s over time, though management declined to put a timeline on it. Aster's oncology revenue contribution reached 11% (up from 10% last year) and is expected to reach the high teens in another 4-5 years.
• Oncology is the growth engine, with a cost: Oncology revenue grew 27% YoY at Aster. QCIL is investing in linear accelerators and oncology blocks across five facilities over the next two years. The trade-off: oncology carries high material cost, which is the primary driver of the 50 bps YoY increase in material intensity.
• ALOS is falling for the right reasons: Aster's ALOS is sub-4 days, driven by oncology daycare (50-60% of oncology revenue), keyhole procedures, robotic surgeries (80-90 per month at MedCity), and quality-driven infection control. QCIL's ALOS is higher at 3.9 days due to a heavier mix of orthopedics, cardiothoracic, and neurosciences. Aster's ALOS has reduced 5-6% over the last 4-5 quarters.
• Non-census beds are high but explained: Aster's 24% non-census bed share is higher than peers because it consistently counts emergency beds, daycare beds, pre-op/post-op beds, and dialysis beds. The shift toward short-stay and daycare procedures is converting some census beds to non-census, which also reduces ALOS.
• ARPP IP growth outlook: Kerala cluster ARPP IP is expected to grow 6-8% in the mid-term (3-4 years). K&M cluster ARPOB, currently at INR 77,000, has another 6-7% headroom; mature Bangalore hospital ARPOB should reach around INR 75,000.

Varun Khanna: "I don't know. I can't really put a number to where it will end up. But my sense is that you'll be mid-60s over a period of time. So, I don't want to draw when, but the how is known to us. I don't think when is a fair answer."

Ancillary Businesses: Labs and Pharmacy Turning Around

• Aster Labs is on a clear margin trajectory: EBITDA margins have moved from -7.6% in FY24 to +7.6% in FY25 to +12.2% YTD FY26, driven by 35% YoY growth in external (non-captive) business, enhanced operating leverage, and improved material cost efficiencies. Revenue grew 17% YoY to INR 39 crore. The key to reaching >20% margins in 2-3 years is increasing non-captive business from 30-31% to over 50% of revenue, supported by a dedicated retail app launching soon.
• Wholesale pharmacy is no longer a drag: A strategic decision to outsource the loss-making portion led to reduced revenues but materially improved profitability. 9M EBITDA margins reached 1.8%, with the most recent quarter at 2.2%, moving the business to positive ROCE for the first time. The business model caps sustainable margins at 3-3.5%, and management is not looking to grow it aggressively.
• Retail pharmacy is a long-tail bet: 203 pharmacies operate under a brand licensing model (49% ownership, 51% by resident individuals) across Telangana, Karnataka, and Kerala. The business is expected to break even in another year or two.

Guidance & Commitments

Key Metrics